GLUT10在乳腺癌中的表达特征及其介导顺铂耐药的机制
该研究通过数据库分析和体外实验探讨GLUT10在乳腺癌中的表达及其在顺铂耐药中的作用。结果显示乳腺癌组织中SLC2A10 mRNA较正常乳腺组织升高1.85倍(P<0.001),且GLUT10通过调节ROS水平介导顺铂耐药,提示其可能成为逆转乳腺癌耐药的新靶点。
要点
- 乳腺癌组织中SLC2A10 mRNA较正常组织升高1.85倍(P<0.001)。
- 敲低SLC2A10升高ROS、增加顺铂敏感性并促进凋亡。
- 过表达SLC2A10降低ROS、降低顺铂敏感性并抑制凋亡。
核心结论
- GLUT10在乳腺癌中高表达,通过调节ROS水平介导顺铂耐药,可能成为逆转耐药的新靶点。
研究设计与样本
- 利用TCGA和GTEx数据库通过GEPIA2和UALCAN平台分析GLUT10表达。
- 体外用SK-BR-3细胞设shScr、shSLC2A10#1和shSLC2A10#2组,MDA-MB-231细胞设空载体和SLC2A10过表达组。
主要发现
- GEPIA2分析显示GLUT10在浸润性乳腺癌等肿瘤中表达高于正常组织,在肾上腺皮质癌等中低于正常组织。
- UALCAN分析显示乳腺癌组织SLC2A10 mRNA较正常乳腺组织升高1.85倍(P<0.001)。
- 乳腺癌细胞SLC2A10 mRNA均高于正常乳腺上皮细胞(均P<0.001),从高到低为Hs 578T(160.5±12.3)、SK-BR-3(115.2±10.5)、MDA-MB-468(50.1±5.2)、T-47D(35.4±4.1)、MCF7(25.6±3.8)。
- SK-BR-3细胞中敲低SLC2A10后ROS相对荧光强度为1.78±0.12和2.05±0.15(均P<0.05),顺铂敏感性增高、集落数减少、凋亡增加。
- MDA-MB-231细胞中过表达SLC2A10后ROS相对荧光强度为0.58±0.09(P<0.05),顺铂敏感性降低、凋亡受抑。
临床怎么用
- GLUT10高表达可能提示乳腺癌对顺铂耐药,检测其表达或有助于个体化治疗决策。
- 靶向GLUT10调控ROS水平可能是逆转乳腺癌顺铂耐药的潜在策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: This study aims to investigate the expression characteristics of GLUT10 in breast cancer and its role in mediating cisplatin resistance, with the goal of providing a new molecular target for personalized breast cancer treatment. Methods: Data from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) databases were analyzed using the GEPIA2 platform to assess pan-cancer expression, while the UALCAN platform was used to analyze expression differences between breast cancer and normal breast tissues. In vitro, SK-BR-3 cells were divided into three groups: shScr (transfected with non-targeting scrambled shRNA), shSLC2A10#1, and shSLC2A10#2. MDA-MB-231 cells were divided into a vector control group and an SLC2A10 overexpression group. Real-time quantitative polymerase chain reaction (RT-qPCR) was used to detect SLC2A10 mRNA expression. Western blotting was used to detect GLUT10 and cleaved caspase-3 protein expression. The CM-H2DCFDA probe was used to measure intracellular reactive oxygen species (ROS) levels. Drug sensitivity and colony formation assays were performed to evaluate cisplatin sensitivity, and flow cytometry was used to detect apoptosis rates. Results: GEPIA2 analysis showed that GLUT10 expression was downregulated in adrenocortical carcinoma, cervical squamous cell carcinoma and adenocarcinoma, and kidney chromophobe tumor tissues compared to normal tissues, whereas it was upregulated in invasive breast cancer, glioma, skin melanoma, and thymoma. UALCAN analysis revealed that SLC2A10 mRNA levels in breast cancer tissues were 1.85-fold higher than in normal breast tissues (P<0.001). RT-qPCR results showed that SLC2A10 mRNA expression levels in breast cancer cell lines, ranked from high to low, were Hs 578T (160.5±12.3), SK-BR-3 (115.2±10.5), MDA-MB-468 (50.1±5.2), T-47D (35.4±4.1), and MCF7 (25.6±3.8), all significantly higher than in normal breast epithelial cells (P<0.001). In SK-BR-3 cells, compared with the shScr group, the shSLC2A10#1 and shSLC2A10#2 groups exhibited increased intracellular ROS levels (relative fluorescence intensity: 1.78±0.12 and 2.05±0.15, respectively; P<0.05), increased cisplatin sensitivity, reduced colony numbers, and promoted cisplatin-induced ROS accumulation and apoptosis. In MDA-MB-231 cells, compared with the vector control group, the SLC2A10 overexpression group showed decreased intracellular ROS levels (relative fluorescence intensity: 0.58±0.09, P<0.05), decreased cisplatin sensitivity, and inhibited cisplatin-induced ROS accumulation and apoptosis. Conclusion: GLUT10 is highly expressed in breast cancer and mediates cisplatin resistance by regulating ROS levels, suggesting it may serve as a novel therapeutic target for reversing drug resistance in breast cancer. 目的: 探讨由溶质载体家族2成员10(SLC2A10)基因编码的葡萄糖转运蛋白10(GLUT10)在乳腺癌中的表达特征,及其在顺铂耐药中的作用机制,为乳腺癌的个体化治疗提供新的分子靶点。 方法: (1)利用癌症基因组图谱(TCGA)和基因型-组织表达(GTEx)数据库资料,通过GEPIA2平台分析GLUT10泛癌表达情况,通过UALCAN平台分析GLUT10在乳腺癌组织与正常乳腺组织中的表达差异。(2)将乳腺癌SK-BR-3细胞设shScr组(转染非靶向乱序shRNA)、shSLC2A10#1组和shSLC2A10#2组,将MDA-MB-231细胞设空载体组和SLC2A10过表达组(转染SLC2A10全长过表达载体),采用反转录定量聚合酶链反应(RT-qPCR)检测细胞中SLC2A10 mRNA的表达,采用蛋白质免疫印迹法检测细胞中GLUT10蛋白和活化型caspase-3的表达,采用5-(和-6)-氯甲基-2′,7′-二氯二氢荧光素二乙酸酯探针检测细胞中活性氧(ROS)水平,采用药物敏感性实验和克隆形成实验观察细胞对顺铂的敏感性,采用流式细胞术检测细胞凋亡率。 结果: GEPIA2分析显示,GLUT10在肾上腺皮质癌、宫颈鳞状细胞癌和腺癌、肾嫌色细胞癌肿瘤组织中的表达水平低于相应正常组织,而在浸润性乳腺癌、胶质细胞瘤、皮肤黑色素瘤和胸腺瘤肿瘤组织中的表达水平高于相应正常组织。UALCAN分析显示,乳腺癌组织中SLC2A10 mRNA水平较正常乳腺组织升高1.85倍(P<0.001)。RT-qPCR检测结果显示,乳腺癌细胞中SLC2A10 mRNA的表达水平从高到低依次为Hs 578T细胞(160.5±12.3)、SK-BR-3细胞(115.2±10.5)、MDA-MB-468细胞(50.1±5.2)、T-47D细胞(35.4±4.1)及MCF7细胞(25.6±3.8),均高于正常乳腺上皮细胞(均P<0.001)。在SK-BR-3细胞中,与shScr组比较,shSLC2A10#1组和shSLC2A10#2组细胞内ROS水平升高(相对荧光强度分别为1.78±0.12和2.05±0.15,均P<0.05),对顺铂的敏感性增高,集落数减少,促进顺铂诱导的ROS水平增加和细胞凋亡。在MDA-MB-231细胞中,与空载体组比较,SLC2A10过表达组的细胞内ROS水平降低(相对荧光强度为0.58±0.09,P<0.05),对顺铂的敏感性降低,抑制顺铂引起的ROS水平增加和细胞凋亡。 结论: GLUT10在乳腺癌中高表达,通过调节乳腺癌细胞内ROS水平介导顺铂耐药,可能成为逆转乳腺癌耐药的新治疗靶点。.
引用
- Wang YF, Cai YL, Yi TX, et al. [Expression characteristics of GLUT10 in breast cancer and its mechanism in mediating cisplatin resistance]. Zhonghua Zhong Liu Za Zhi. 2026. PMID: 42595549. doi:10.3760/cma.j.cn112152-20251018-00521
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。